These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 21489624

  • 1. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
    Oyekunle AA, Castagnetti F, Gugliotta G, Soverini S, Baccarani M, Rosti G.
    Leuk Res; 2011 Jul; 35(7):e118-20. PubMed ID: 21489624
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dasatinib in chronic myelogenous leukemia.
    Chu SC, Tang JL, Li CC.
    N Engl J Med; 2006 Sep 07; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
    [No Abstract] [Full Text] [Related]

  • 5. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.
    N Engl J Med; 2006 Jun 15; 354(24):2531-41. PubMed ID: 16775234
    [Abstract] [Full Text] [Related]

  • 6. Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
    Faber E, Mojzikova R, Plachy R, Rozmanova S, Stastny M, Divoka M, Jarosova M, Indrak K, Divoky V.
    Leuk Res; 2010 Apr 15; 34(4):e91-3. PubMed ID: 19811824
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
    Yeh CH, Abdool A, Bruey JM.
    Cancer Biomark; 2010 Apr 15; 7(6):295-303. PubMed ID: 21694468
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
    Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW.
    J Clin Oncol; 2010 Apr 10; 28(11):e169-71; author reply e172. PubMed ID: 20194843
    [No Abstract] [Full Text] [Related]

  • 12. CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?
    Goldman J.
    Lab Hematol; 2004 Apr 10; 10(3):181-4. PubMed ID: 15529444
    [No Abstract] [Full Text] [Related]

  • 13. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.
    Am J Hematol; 2012 Nov 10; 87(11):E125-8. PubMed ID: 23044928
    [Abstract] [Full Text] [Related]

  • 14. Mutational analysis in chronic myeloid leukemia: when and what to do?
    Branford S, Hughes TP.
    Curr Opin Hematol; 2011 Mar 10; 18(2):111-6. PubMed ID: 21245758
    [Abstract] [Full Text] [Related]

  • 15. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai A, Fekete S, Barta A, Ujj G, Lueff S, Sipos A, Adám E, Bors A, Reményi P, Masszi T, Tordai A, Andrikovics H.
    Acta Haematol; 2012 Mar 10; 127(1):34-42. PubMed ID: 22005133
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
    Beel K, Janssens A, Verhoef G, Vandenberghe P.
    Leuk Res; 2009 Dec 10; 33(12):1703-5. PubMed ID: 19457553
    [Abstract] [Full Text] [Related]

  • 20. BCR-ABL mutant kinetics in CML patients treated with dasatinib.
    Nicolini FE, Chabane K, Tigaud I, Michallet M, Magaud JP, Hayette S.
    Leuk Res; 2007 Jun 10; 31(6):865-8. PubMed ID: 17208297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.